# A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

> **NCT05071729** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 31 (actual)

## Conditions studied

- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

## Interventions

- **DRUG:** Elinzanetant (BAY3427080)

## Key facts

- **NCT ID:** NCT05071729
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2022-10-19
- **Final completion:** 2022-10-19
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05071729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05071729, "A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05071729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*